SCHEMBL3605235

SCHEMBL3605235

Cc1nn(C)c(Oc2cc(Br)ccc2Cl)c1C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NMT1 P30419 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
GPBAR1 Q8TDU6 1/20 0.35
MAPT P10636 3/20 0.35
KDM4E B2RXH2 2/20 0.35
HTR2A P28223 1/20 0.34
SLC6A4 P31645 1/20 0.34
KCNH2 Q12809 1/20 0.34
LMNA P02545 2/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
GALR3 O60755 1/20 0.33
HTT P42858 1/20 0.33
FPR2 P25090 1/20 0.33
PROKR1 Q8TCW9 1/20 0.33
MAPK8 P45983 1/20 0.33
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3609589 0.89 ALDH1A1 (0.39) NMT1SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL3613853 0.83 SMN1; SMN2 (0.57) NMT1SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL3613724 0.83 ALDH1A1 (0.36) NMT1SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL3610953 0.82 CYP4F2 (0.37) NMT1SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL3615674 0.81 NMT1 (0.33) NMT1SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL3614193 0.80 AR (0.40) SMN1; SMN2CYP1A2CYP2C9CYP2C19GPBAR1
SCHEMBL3607854 0.80 SMN1; SMN2 (0.44) SMN1; SMN2CYP1A2CYP2C9CYP2C19GPBAR1
SCHEMBL3605106 0.80 GPBAR1 (0.36) SMN1; SMN2CYP1A2CYP2C9CYP2C19GPBAR1
SCHEMBL3603069 0.77 ALDH1A1 (0.38) SMN1; SMN2CYP1A2CYP2C9CYP2C19GPBAR1
SCHEMBL3614548 0.77 GPBAR1 (0.32) SMN1; SMN2CYP1A2CYP2C9CYP2C19GPBAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016396-A1 PYRAZOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-01-21 US disclosed
EP-2128138-A1 PYRAZOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016396-A1 PYRAZOLE COMPOUND SLC5A1, SLC5A2, GLP1R NMT1 1023/4885SMN1; SMN2 4515/4885CYP1A2 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.